Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has submitted newspaper cuttings of its Q1 FY26 unaudited financial results, published on 5 August 2025 in Economic Times, Indian Express, and Financial Express (Gujarati edition). On a consolidated basis, total income from operations rose to ₹1,710.72 crore from ₹1,561.73 crore in Q1 FY25, a growth of about 9.5%. Net profit after tax grew to ₹154.38 crore from ₹134.71 crore, up roughly 14.6% year-on-year, and EPS rose to ₹7.85 from ₹6.84. However, on a standalone basis, profit after tax fell sharply to ₹103.52 crore from ₹176.19 crore, a decline of around 41% year-on-year, even though standalone revenue was largely flat at ₹1,494.17 crore. The divergence suggests subsidiaries drove the consolidated profit growth.
Consolidated earnings show healthy revenue and profit growth, which is positive for shareholders, but the sharp standalone profit decline may raise questions about core domestic business performance. Investors should monitor the next quarterly update for clarity on whether the standalone weakness is temporary or structural.